News & Updates Press Release Kyle Kostesich 2/18/20 Press Release Kyle Kostesich 2/18/20 Phosplatin Therapeutics Announces Publication in OncoImmunology Read More Press Release Kyle Kostesich 2/11/20 Press Release Kyle Kostesich 2/11/20 Phosplatin Therapeutics presents positive data from two phase I studies in metastatic castrate-resistant prostate cancer patients at the Genitourinary Cancers Symposium Read More Press Release Kyle Kostesich 11/7/19 Press Release Kyle Kostesich 11/7/19 Phosplatin Therapeutics Completes First Fully-Robotic cGMP Drug Product Batch of PT-112 with Baxter BioPharma Solutions’ Halle/Westfalen Germany Facility Read More Press Release Kyle Kostesich 9/29/19 Press Release Kyle Kostesich 9/29/19 Phosplatin Therapeutics Convenes Clinical Advisory Board with Prostate Cancer Experts During ESMO 2019 Annual Congress Read More Press Release Kyle Kostesich 10/25/18 Press Release Kyle Kostesich 10/25/18 Phosplatin Therapeutics receives US FDA Orphan Drug designation for the use of PT-112 in patients with Thymoma and Thymic Carcinoma Read More Press Release Kyle Kostesich 10/22/18 Press Release Kyle Kostesich 10/22/18 Phosplatin honored at the European Society of Medical Oncology (ESMO) 2018 Annual Meeting Read More Press Release Kyle Kostesich 2/7/18 Press Release Kyle Kostesich 2/7/18 Phosplatin Therapeutics Announces First Cohort Enrolled in Phase I / II Trial of PT-112 in Relapsed / Refractory Multiple Myeloma, and Receipt of FDA Orphan Drug Designation Read More Press Release Kyle Kostesich 9/9/17 Press Release Kyle Kostesich 9/9/17 Phosplatin Therapeutics Announces Collaboration with Pfizer and Merck KGaA, Darmstadt, Germany to Evaluate Combination of PT-112 and Avelumab in Phase I / II Studies Read More Press Release Kyle Kostesich 9/26/16 Press Release Kyle Kostesich 9/26/16 SciClone Announces Progress In Advancing Clinical Pipeline For China Pharmaceuticals Market Read More Press Release Kyle Kostesich 8/18/15 Press Release Kyle Kostesich 8/18/15 Phosplatin Therapeutics Announces the Execution of Regional Licensing Agreement for its Novel Therapeutic Agent in Oncology, PT-112 Read More Press Release Kyle Kostesich 7/10/15 Press Release Kyle Kostesich 7/10/15 Phosplatin Therapeutics saddened by the loss of Rathindra Bose, inventor of phosphaplatins Read More Press Release Kyle Kostesich 6/23/15 Press Release Kyle Kostesich 6/23/15 Phosplatin Therapeutics Appoints José Jimeno, M.D., PhD as Chief Medical Officer Read More Press Release Kyle Kostesich 10/21/14 Press Release Kyle Kostesich 10/21/14 Phosplatin Therapeutics Announces First Patients Enrolled in Phase I First-in-Human Clinical Trial in Solid Tumors Read More Newer Posts
Press Release Kyle Kostesich 2/18/20 Press Release Kyle Kostesich 2/18/20 Phosplatin Therapeutics Announces Publication in OncoImmunology Read More
Press Release Kyle Kostesich 2/11/20 Press Release Kyle Kostesich 2/11/20 Phosplatin Therapeutics presents positive data from two phase I studies in metastatic castrate-resistant prostate cancer patients at the Genitourinary Cancers Symposium Read More
Press Release Kyle Kostesich 11/7/19 Press Release Kyle Kostesich 11/7/19 Phosplatin Therapeutics Completes First Fully-Robotic cGMP Drug Product Batch of PT-112 with Baxter BioPharma Solutions’ Halle/Westfalen Germany Facility Read More
Press Release Kyle Kostesich 9/29/19 Press Release Kyle Kostesich 9/29/19 Phosplatin Therapeutics Convenes Clinical Advisory Board with Prostate Cancer Experts During ESMO 2019 Annual Congress Read More
Press Release Kyle Kostesich 10/25/18 Press Release Kyle Kostesich 10/25/18 Phosplatin Therapeutics receives US FDA Orphan Drug designation for the use of PT-112 in patients with Thymoma and Thymic Carcinoma Read More
Press Release Kyle Kostesich 10/22/18 Press Release Kyle Kostesich 10/22/18 Phosplatin honored at the European Society of Medical Oncology (ESMO) 2018 Annual Meeting Read More
Press Release Kyle Kostesich 2/7/18 Press Release Kyle Kostesich 2/7/18 Phosplatin Therapeutics Announces First Cohort Enrolled in Phase I / II Trial of PT-112 in Relapsed / Refractory Multiple Myeloma, and Receipt of FDA Orphan Drug Designation Read More
Press Release Kyle Kostesich 9/9/17 Press Release Kyle Kostesich 9/9/17 Phosplatin Therapeutics Announces Collaboration with Pfizer and Merck KGaA, Darmstadt, Germany to Evaluate Combination of PT-112 and Avelumab in Phase I / II Studies Read More
Press Release Kyle Kostesich 9/26/16 Press Release Kyle Kostesich 9/26/16 SciClone Announces Progress In Advancing Clinical Pipeline For China Pharmaceuticals Market Read More
Press Release Kyle Kostesich 8/18/15 Press Release Kyle Kostesich 8/18/15 Phosplatin Therapeutics Announces the Execution of Regional Licensing Agreement for its Novel Therapeutic Agent in Oncology, PT-112 Read More
Press Release Kyle Kostesich 7/10/15 Press Release Kyle Kostesich 7/10/15 Phosplatin Therapeutics saddened by the loss of Rathindra Bose, inventor of phosphaplatins Read More
Press Release Kyle Kostesich 6/23/15 Press Release Kyle Kostesich 6/23/15 Phosplatin Therapeutics Appoints José Jimeno, M.D., PhD as Chief Medical Officer Read More
Press Release Kyle Kostesich 10/21/14 Press Release Kyle Kostesich 10/21/14 Phosplatin Therapeutics Announces First Patients Enrolled in Phase I First-in-Human Clinical Trial in Solid Tumors Read More
